AAPL 192.4902 0.7591% MSFT 429.38 0.9498% GOOG 179.04 0.325% GOOGL 177.45 0.2996% AMZN 182.02 -0.8282% NVDA 947.4001 -0.0422% META 464.53 -0.9193% TSLA 186.0554 6.3478% TSM 153.42 -0.0847% LLY 803.85 2.6392% V 276.17 -0.8509% AVGO 1399.41 -1.0339% JPM 198.68 1.585% UNH 522.2967 0.9796% NVO 134.5401 1.2265% WMT 64.9 1.1218% LVMUY 166.815 -1.2052% XOM 118.03 -0.5393% LVMHF 846.034 0.1224% MA 457.885 -0.3862%

Elanco Animal Health

Healthcare US ELAN


Last update at 2024-05-21T18:49:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -66.00000M -567.00000M -672.00000M 78.20M 114.10M
Minority interest - - - - -
Net income -74.00000M -472.00000M -560.10000M 67.90M 86.50M
Selling general administrative 1266.00M 1404.00M 996.60M 760.20M 735.20M
Selling and marketing expenses - - 996.00M - -
Gross profit 2505.00M 2631.00M 1606.70M 1600.70M 1493.00M
Reconciled depreciation 528.00M 556.00M 516.90M 314.50M 296.00M
Ebit 358.00M 297.00M 101.50M 342.60M 442.60M
Ebitda 886.00M 853.00M 461.40M 543.00M 640.00M
Depreciation and amortization 528.00M 556.00M 359.90M 200.40M 197.40M
Non operating income net other -32.00000M -5.00000M 178.30M -27.40000M -41.30000M
Operating income 358.00M 297.00M 101.50M 342.60M 313.80M
Other operating expenses 4028.00M 4463.00M 3350.10M 2701.00M 2753.00M
Interest expense 241.00M 236.00M 149.80M 78.90M 29.60M
Tax provision 8.00M -95.00000M -111.90000M 10.30M 27.60M
Interest income - - - 78.90M 29.60M
Net interest income -241.00000M -236.00000M -149.80000M -78.90000M -29.60000M
Extraordinary items - - - - -
Non recurring 183.00M 628.00M 623.70M 185.50M 128.80M
Other items - - - - -
Income tax expense 8.00M -95.00000M -111.90000M 10.30M 27.60M
Total revenue 4418.00M 4765.00M 3273.30M 3071.00M 3066.80M
Total operating expenses 2115.00M 2329.00M 1683.50M 1230.70M 1179.20M
Cost of revenue 1913.00M 2134.00M 1666.60M 1470.30M 1573.80M
Total other income expense net -424.00000M -864.00000M -773.50000M -264.40000M -170.10000M
Discontinued operations - - - - -
Net income from continuing ops -74.00000M -472.00000M -560.10000M 67.90M 86.50M
Net income applicable to common shares -78.00000M -472.00000M -560.10000M 67.90M 86.50M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 15491.00M 16483.00M 17692.70M 8985.80M 8956.70M
Intangible assets 4842.00M 5587.00M 6387.30M 2482.80M 2453.00M
Earning assets - - - - -
Other current assets 394.00M 237.00M 256.30M 87.40M 113.90M
Total liab 8202.00M 8945.00M 9216.80M 3438.90M 3759.20M
Total stockholder equity 7289.00M 7538.00M 8475.90M 5546.90M 5197.50M
Deferred long term liab - - - - -
Other current liab 924.00M 746.00M 872.20M 455.40M 368.90M
Common stock - - - - -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -1057.00000M -949.00000M -477.20000M 84.30M 16.40M
Other liab 941.00M 1150.00M 1340.90M 228.20M 337.80M
Good will 5993.00M 6172.00M 6224.80M 2989.60M 2958.00M
Other assets 193.00M 183.00M 127.30M 78.90M 51.30M
Cash 345.00M 638.00M 494.70M 334.00M 474.80M
Cash and equivalents - - - - -
Total current liabilities 1702.00M 1643.00M 2076.30M 818.50M 970.70M
Current deferred revenue - 185.00M 148.60M 116.00M 367.60M
Net debt 5491.00M 5681.00M 5632.20M 2021.00M 1997.50M
Short term debt 388.00M 294.00M 554.50M 24.50M 29.00M
Short long term debt 388.00M 294.00M 554.50M 24.50M 29.00M
Short long term debt total 5836.00M 6319.00M 6126.90M 2355.00M 2472.30M
Other stockholder equity 8738.00M 8696.00M 8650.10M 5636.30M 5403.30M
Property plant equipment 999.00M 1222.00M 1316.30M 1040.30M 922.40M
Total current assets 3279.00M 3276.00M 3416.50M 2373.10M 2504.90M
Long term investments - - - 21.10M 15.30M
Net tangible assets -3546.00000M -4325.00000M -4136.20000M 74.50M -265.30000M
Short term investments - - - - -
Net receivables 1002.00M 1028.00M 1076.70M 889.90M 709.40M
Long term debt 5448.00M 6025.00M 5572.40M 2330.50M 2443.30M
Inventory 1538.00M 1373.00M 1578.10M 1050.70M 1004.10M
Accounts payable 390.00M 418.00M 501.00M 222.60M 205.20M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -392.00000M -209.00000M 303.00M -173.70000M -222.20000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity -1057.00000M -949.00000M -477.20000M 84.30M 16.40M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 378.00M 387.00M 347.80M 185.00M 103.10M
Deferred long term asset charges - - - - -
Non current assets total 12212.00M 13207.00M 14276.20M 6612.70M 6451.80M
Capital lease obligations - - - - -
Long term debt total - - - 2330.50M 2443.30M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -179.00000M -530.00000M 32.70M -234.80000M -127.00000M
Change to liabilities -98.00000M -120.00000M 369.30M -29.20000M 116.10M
Total cashflows from investing activities -179.00000M -530.00000M -4779.20000M -234.80000M -127.00000M
Net borrowings -518.00000M 241.00M 3750.20M -121.10000M 2468.00M
Total cash from financing activities -549.00000M 210.00M 4953.90M -304.80000M -35.20000M
Change to operating activities -109.00000M 31.00M -122.90000M 7.00M -3.20000M
Net income -78.00000M -472.00000M -560.10000M 67.90M 86.50M
Change in cash -293.00000M 132.00M 160.30M -332.40000M 354.10M
Begin period cash flow 638.00M 506.00M 345.10M 677.50M 323.40M
End period cash flow 345.00M 638.00M 505.40M 345.10M 677.50M
Total cash from operating activities 452.00M 483.00M -41.00000M 224.10M 487.30M
Issuance of capital stock 0.00000M 0.00000M 1219.90M 0.00000M 1659.70M
Depreciation 682.00M 716.00M 516.90M 314.50M 296.00M
Other cashflows from investing activities -42.00000M -8.00000M -4677.30000M -94.40000M 7.50M
Dividends paid - - - - -
Change to inventory -269.00000M 27.00M -94.70000M -33.10000M -20.10000M
Change to account receivables 14.00M -3.00000M 14.00M -172.40000M -122.00000M
Sale purchase of stock - - 1219.90M - 1659.70M
Other cashflows from financing activities 941.00M 1033.00M 4685.50M -183.70000M -1687.40000M
Change to netincome 22.00M 326.00M -278.70000M 36.80M 13.50M
Capital expenditures 184.00M 197.00M 310.90M 197.40M 134.50M
Change receivables 14.00M -25.00000M 14.00M -172.40000M -122.00000M
Cash flows other operating 179.00M 434.00M -7.70000M 39.60M 117.30M
Exchange rate changes - - - - -
Cash and cash equivalents changes -276.00000M 163.00M 133.70M -315.50000M 325.10M
Change in working capital -462.00000M -87.00000M 165.70M -227.70000M -29.20000M
Stock based compensation 59.00M 66.00M 47.70M 49.40M 26.00M
Other non cash items 308.00M 414.00M -86.40000M 19.90M 168.70M
Free cash flow 268.00M 286.00M -351.90000M 26.70M 352.80M


  • Previous Close 17.00
  • Market Cap6736.55M
  • Volume1891066
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA973.00M
  • Revenue TTM4367.00M
  • Revenue Per Share TTM8.89
  • Gross Profit TTM 2498.00M
  • Diluted EPS TTM-2.32

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Elanco Animal Health
-0.235 1.38% 16.77 - 15.20 1.54 1.10 2.81 -63.2812
Zoetis Inc
-1.65 0.95% 172.74 40.18 30.96 10.67 17.60 11.27 26.18
Merck KGaA ADR
-0.19 0.53% 35.92 21.25 14.93 3.10 2.14 3.60 12.98
MERCK Kommanditgesellschaft auf Aktien
-4.75 2.60% 178.25 21.73 14.95 3.16 2.15 3.56 12.82
Takeda Pharmaceutical Co Ltd ADR
-0.09 0.68% 13.19 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News


Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. The company was founded in 1954 and is headquartered in Greenfield, Indiana.

Elanco Animal Health

2500 Innovation Way, Greenfield, IN, United States, 46140

Key Executives

Name Title Year Born
Mr. Jeffrey N. Simmons Pres, CEO & Director 1967
Mr. Todd S. Young Exec. VP of Corp. Governance and Strategy & CFO 1972
Mr. Ramiro Martin Cabral Exec. VP & Pres of Elanco International 1972
Mr. James M. Meer Sr. VP & Chief Accounting Officer 1970
Mr. Chris Keeley Sr. VP & Chief Information Officer NA
Mr. David S. Kinard Exec. VP of HR Corp. Affairs & Admin. 1967
Ms. Marcela A. Kirberger Exec. VP, Gen. Counsel & Corp. Sec. 1967
Mr. David Alan Urbanek Exec. VP of Manufacturing & Quality 1967
Mr. Shawn McKee Sr. VP of U.S. Companion Animal NA
Mr. Larbi Van Lier Sr. VP of Asia NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).